Compare SLRC & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLRC | AGMB |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 691.2M | 738.7M |
| IPO Year | 2007 | 2024 |
| Metric | SLRC | AGMB |
|---|---|---|
| Price | $12.64 | $13.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $15.14 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 414.4K | 89.6K |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | ★ 10.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.09 | N/A |
| Revenue Next Year | N/A | $17.86 |
| P/E Ratio | $26.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.13 | $8.75 |
| 52 Week High | $16.75 | $17.82 |
| Indicator | SLRC | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 49.30 |
| Support Level | $12.47 | $9.54 |
| Resistance Level | $13.33 | $14.19 |
| Average True Range (ATR) | 0.25 | 1.01 |
| MACD | -0.04 | -0.13 |
| Stochastic Oscillator | 22.76 | 11.48 |
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. The company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The company invests principally in leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans and equity securities.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.